Navigation Links
Study shows chemotherapy improves survival among older breast cancer patients
Date:5/13/2009

The average age of a woman diagnosed with breast cancer is 63, so it is critical to have effective proven, therapies for an older patient population. But older women with breast cancer are underrepresented in clinic trials, so there is little data on the effects of chemotherapy used in addition to other therapies such as surgery.

A new study, published in the May 14 issue of The New England Journal of Medicine, shows that chemotherapy in addition to the surgery or surgery and radiation improves survival among older women.

The study was conducted with 600 women through the Cancer and Leukemia Group B of the National Cancer Institute's Clinical Trials Cooperative Group Program.

"This study is important because it is among the first several trials specifically targeted to older women with early-stage breast cancer and shows that chemotherapy can make a difference," said Hyman Muss, M.D. professor of medicine at the University of North Carolina at Chapel Hill and a member of UNC Lineberger Comprehensive Cancer Center, and corresponding author on the study.

The study compared a combination of chemotherapy drugs the standard treatment to a single drug in patients with early-stage breast cancer aged 65 and older. The combination therapy provided significantly better outcomes than a single drug treatment.

Similar studies involving women younger than 70 years of age have also shown that combination therapies provide better outcomes.

For this trial, the standard chemotherapy consisted of either cyclophosphamide, methotrexate, and fluouracil (CMF) or doxorubicin plus cyclophosphamide. The single drug was the oral drug, capecitabine.

Because patients often prefer oral to intravenous chemotherapy, a new effective oral agent for multi-drug treatment would be useful in treating older women with breast cancer. But the study showed that patients who were randomly assigned to capecitabine were twice as likely to have a relapse, and at three-years after completing therapy, the rate of relapse-free survival was 68 percent in the capecitabine group versus 85 percent in the standard-chemotherapy group.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. New research confirms milestone study on blood pressure meds
2. UCLA study shows traumatic brain injury haunts children for years
3. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
4. A feasible, simple and convenient model for study of rectal carcinoma
5. New Study Shows Stresses of Economic Downturn on Womens Relationships
6. New Economic Impact Study: Obama Administration Implementation of Bush-Era Medicare Regulation Will Cost U.S. $2.5 Billion in Business Activity, Cut Over 30,000 Jobs
7. 22-year study finds adults arent active enough
8. Researchers study the human factor in spread of pandemic illness
9. Eye Disease, Cognitive Decline Linked in Study
10. Access to care leads Americans priorities in first-ever public study of health value
11. Access to Care Leads Americans Priorities in First-Ever Public Study of Health Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... today announced the addition of Victor Giamos, MD to their medical staff, ... and Managing Partner at North Shore Eye Care, a division of SightMD. Dr. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide ... wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue their ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. ... the official journal of The American Society for Aesthetic Plastic Surgery, in which ... is designed to correct drooping, retracted lower eyelids, which usually result from genetics, ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... latest in 3-D scanning device which is capable of taking digital impressions of teeth ... dentistry, such as CAD CAM restorations , in terms of speed, efficiency and ...
(Date:1/15/2017)... ... ... In this role, Courtney will be responsible for developing new business initiatives ... mark. This certification program was created by ASL and the nonprofit Asthma and Allergy ... for the 60+ million people living in the U.S. with asthma and allergies. Courtney ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... According to a new ... by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical ... User - Global Forecast to 2021", published by ... 2016 to 2021. This market is expected to ... 715.4 Million in 2016, at a CAGR of ...
(Date:1/13/2017)... January 13, 2017 The 2016 election ... with several states voting in favor of legalizing cannabis for ... Cannabis market in the U.S. In addition, the state of ... in annual cannabis products sales. The ArcView Group has published ... the legal cannabis sales in the U.S. last year reached $6.7 ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology: